Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1141-1150 of 1,460) with videos related to

Pageof 146
Sort By:
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2007
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjectsJorge A Tavel, Julie E Martin, Grace G Kelly, et al.
Vaccine|July 13, 2024
Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infantsFlorencia A Bonnin, Laura B Talarico, Fausto M Ferolla, et al.
Plos One|August 14, 2010
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicityBarney S Graham, M Juliana McElrath, Michael C Keefer, et al.
Viruses|March 6, 2019
Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and AlpacasDanielle R Adney, Lingshu Wang, Neeltje van Doremalen, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Journal of Virology|October 23, 2009
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationCheng Cheng, Jason G D Gall, Martha Nason, et al.
Journal of Virology|July 1, 2011
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01Yuxing Li, Sijy O'Dell, Laura M Walker, et al.
Vaccine|February 27, 2021
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataFlor M Munoz, Jakob P Cramer, Cornelia L Dekker, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
Pageof 146

Showing results (1141-1150 of 1,460) with videos related to

Sort By:
Pageof 146
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2007
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjectsJorge A Tavel, Julie E Martin, Grace G Kelly, et al.
Vaccine|July 13, 2024
Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infantsFlorencia A Bonnin, Laura B Talarico, Fausto M Ferolla, et al.
Plos One|August 14, 2010
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicityBarney S Graham, M Juliana McElrath, Michael C Keefer, et al.
Viruses|March 6, 2019
Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and AlpacasDanielle R Adney, Lingshu Wang, Neeltje van Doremalen, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Journal of Virology|October 23, 2009
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationCheng Cheng, Jason G D Gall, Martha Nason, et al.
Journal of Virology|July 1, 2011
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01Yuxing Li, Sijy O'Dell, Laura M Walker, et al.
Vaccine|February 27, 2021
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataFlor M Munoz, Jakob P Cramer, Cornelia L Dekker, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
Pageof 146